Sep 29,2023

Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

DexCom announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

View Analyst & Ambassador Comments
Go to original news
Sep 29,2023

Samuel Künzli succeeds Niklaus Ramseier as CFO and member of the Executive Board at Ypsomed

Ypsomed announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

View Analyst & Ambassador Comments
Go to original news
Sep 30,2023 TOP STORY

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Making its debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD), Shenzhen Sibionics Technology Co., Ltd. will unveil its flagship product, the SIBIONICS GS1 Continuous Glucose Monitoring System. Established in 2015, SIBIONICS is a high-tech firm specializing in the integration of implantable medical hardware technology and artificial intelligence algorithms. SIBIONICS CGM captured a market share of nearly 20% within its inaugural year of launch in China, making it the leading domestically produced CGM, offering calibration-free and scan-free features, as well as 14 days of real-time continuous monitoring. The product is on the verge of obtaining CE certification from the European Union. Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management powered by SIBIONICS CGM technology, offering continuous real-time monitoring ketone levels up to 14 days.

PRODUCT

#cgm

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 26,2019

A Digital Diabetes Prevention Program (Transform) for Adults With Prediabetes: Secondary Analysis

This study aimed to investigate the effects of a novel digital therapeutic diabetes prevention program (DPP) (Transform) on weight loss, body mass index (BMI), exercise frequency, and work absenteeism. It was a secondary analysis of retrospective data of adults with prediabetes who were enrolled in the Transform DPP from December 2016 to December 2017. The program incorporates interactive mobile computing, remote monitoring, an evidence-based curriculum, behavior tracking tools, health coaching, and online peer support to prevent or delay the onset of type 2 diabetes. The sample (N=273) comprised people with prediabetes who completed 4 months of the Transform program. On average, participants increased their exercise frequency by 1.7 days per week, and absenteeism was reduced by almost half a day per month. These results suggest that the digital therapeutic DPP (Transform) is effective at preventing type 2 diabetes through a significant reduction in body weight and an increase of physical activity. A prospective, controlled clinical study is warranted to validate these findings.

CLINICAL STUDY

#dtx

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023

Major Players in the Insulin Patch Pumps Global Market to 2030 Include Callnovo, Medtronic, Ypsomed, Sanofi and More

The global insulin patch pumps market grew from $1.18 billion in 2022 to $1.28 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The insulin patch pumps market is expected to grow to $1.83 billion in 2027 at a CAGR of 9.3%, according to the research publisher. North America was the largest region in the insulin patch pumps market in 2022.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence

Nemaura Medica, a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development, to assist in development of its AI Health Coach, and strengthen outcomes in its CGM based metabolic and Type 2 Diabetes programs. Dr. Faz Chowdhury, Chief Executive Officer, stated, “We are excited to be working with Nikolai to leverage our CGM data to give better insights to members. The use of AI based models is becoming more widespread, and we believe they have a vital role to play in the healthcare and lifestyle sector. Deeper personalised insights better engage users, and the capability of AI means this can be scaled efficiently”.

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023 TOP STORY

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Senseonics, a medical technology company focused on the development of implantable continuous glucose monitoring (CGM) systems, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient. The ENHANCE study is designed to evaluate the accuracy and safety of the Eversense system for one year. Over 165 adult subjects were inserted with Eversense systems in four centers across the United States. Data gathered in this study was also used to support the FDA submission for the integrated continuous glucose monitoring, iCGM, designation earlier in 2023. An investigational device exemption (“IDE”) supplement was submitted and approved for expansion of the study to allow for pediatric patients 14 to 18 years of age and the first pediatric study participants were enrolled in Q2 2023.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023

MicroTech Medical's Interim Report Shows 54% Increase in Revenues

MicroTech Medical, a Chinese medical equipment start-up specializing in the development and manufacturing of medical devices, with a particular focus on diabetes management and chronic disease management, announced its interim report on the company's earnings in 2023. For the six months ended June 30, 2023, we recorded operating income of RMB110.8 million, representing an increase of 54.3% from RMB71.8 million for the six months ended June 30, 2022. For the six months ended June 30, 2023, we recorded gross profit of RMB57.6 million, representing an increase of 81.3% from RMB31.8 million for the six months ended June 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Sep 27,2023

ACON joins Medica 2023 Conference in Germany

ACON Laboratories announces its participation in the MEDICA 2023 conference held in Düsseldorf Germany in between 13-16th of November 2023.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 27,2023

ABBOTT HOSTS CONFERENCE CALL FOR THIRD-QUARTER EARNINGS

Abbott (NYSE: ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES